Patents by Inventor Christopher John Porter
Christopher John Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975073Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: GrantFiled: June 26, 2023Date of Patent: May 7, 2024Assignees: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20240050573Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.Type: ApplicationFiled: June 28, 2023Publication date: February 15, 2024Applicant: Monash UniversityInventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20230338552Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: June 26, 2023Publication date: October 26, 2023Applicants: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20230119819Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.Type: ApplicationFiled: May 6, 2022Publication date: April 20, 2023Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
-
Patent number: 11608345Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: GrantFiled: December 19, 2018Date of Patent: March 21, 2023Assignees: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Sifei Han, Luojuan Hu, Ketki Karanam, Christopher John Porter, Tim Quach, Rishab R. Shyam, Jamie Simpson, Natalie Trevaskis
-
Publication number: 20230062834Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: December 19, 2018Publication date: March 2, 2023Inventors: Daniel Kenneth BONNER, Sifei HAN, Luojuan HU, Ketki KARANAM, Christopher John PORTER, Tim QUACH, Rishab R. SHYAM, Jamie SIMPSON, Natalie TREVASKIS
-
Publication number: 20220395513Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: August 4, 2022Publication date: December 15, 2022Applicants: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20220339168Abstract: The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.Type: ApplicationFiled: September 21, 2020Publication date: October 27, 2022Inventors: Natalie TREVASKIS, Christopher John PORTER, Tim QUACH, Sifei HAN, Enyuan CAO, Luojuan HU, Matthew WATT
-
Patent number: 11324832Abstract: The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.Type: GrantFiled: December 21, 2016Date of Patent: May 10, 2022Assignee: Endosome Therapeutics, Inc.Inventors: Nigel W. Bunnett, Christopher John Porter, Derek Cole, Gareth Hicks, Junya Shirai, Gavin Hirst, Luigi Aurelio
-
Publication number: 20220125933Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: February 28, 2020Publication date: April 28, 2022Inventors: Joseph BOLEN, Daniel Kenneth BONNER, Ketki KARANAM, Christopher John PORTER, Jamie SIMPSON, Natalie TREVASKIS, Dan ZHENG, Nathania LEONG, Garima SHARMA, Mitchell MCINERNEY, Tim QUACH, Sifei HAN
-
Publication number: 20210300962Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: August 2, 2019Publication date: September 30, 2021Inventors: Daniel Kenneth BONNER, Ketki KARANAM, Jamie SIMPSON, Christopher John PORTER, Natalie TREVASKIS, Tim QUACH, Sifei HAN, Luojuan HU
-
Publication number: 20210268115Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: February 5, 2021Publication date: September 2, 2021Inventors: Daniel Kenneth BONNER, Rishab R. SHYAM, Jamie SIMPSON, Christopher John PORTER, Natalie TREVASKIS, Tim QUACH, Sifei HAN, Luojuan HU
-
Patent number: 9443710Abstract: Techniques are described for performing performance maintenance on a mass spectrometer. Pre-maintenance testing is performed that automating execution of a test sequence in response to a first user interface selection. The maintenance activity performed upon completion of said pre-maintenance testing. Post-maintenance testing is preformed upon completion of said maintenance activity. The post-maintenance testing includes automating execution of the test sequence in response to a second user interface selection. A benchmark comparison is performed to determine whether performance of the mass spectrometer has degraded as a result of performing the maintenance activity, wherein said benchmark comparison is performed automatically in response to completing said post-maintenance testing.Type: GrantFiled: September 7, 2012Date of Patent: September 13, 2016Assignee: Waters Technologies CorporationInventors: Ian Thomas Platt, Timothy Charles Ruck, Almas Khan, Christopher John Porter
-
Patent number: 9396915Abstract: Automated installation processing of a mass spectrometer is described. Software is executed providing a user interface for controlling the installation process. Manual setup operations in connection with physical installation of the mass spectrometer are performed. Instrument level testing of the mass spectrometer is performed. The instrument level testing includes automating execution of a first test sequence in response to a first user interface selection. The first test sequence includes one or more performance tests whereby mass spectral data characterizing observed performance of the mass spectrometer is compared to predetermined performance criteria. System level testing of functionality of the mass spectrometer in combination with one or more other components is performed upon successful completion of said instrument level testing. The system level testing includes automating execution of a second test sequence in response to a second user interface selection.Type: GrantFiled: November 30, 2012Date of Patent: July 19, 2016Assignee: Waters Technologies CorporationInventors: Ian Thomas Platt, Timothy Charles Ruck, Almas Khan, Christopher John Porter
-
Publication number: 20140239171Abstract: Techniques are described for performing performance maintenance on a mass spectrometer. Pre-maintenance testing is performed that automating execution of a test sequence in response to a first user interface selection. The maintenance activity performed upon completion of said pre-maintenance testing. Post-maintenance testing is preformed upon completion of said maintenance activity. The post-maintenance testing includes automating execution of the test sequence in response to a second user interface selection. A benchmark comparison is performed to determine whether performance of the mass spectrometer has degraded as a result of performing the maintenance activity, wherein said benchmark comparison is performed automatically in response to completing said post-maintenance testing.Type: ApplicationFiled: September 7, 2012Publication date: August 28, 2014Applicant: WATERS TECHNOLOGIES CORPORATIONInventors: Ian Thomas Platt, Timothy Charles Ruck, Almas Khan, Christopher John Porter